Kimberly-Clark completes USD 48.7bn acquisition of Kenvue

Kimberly-Clark completed its acquisition of consumer health group Kenvue on 2 November 2026, a deal initially valued at approximately USD 48.7bn. The enlarged group combines Kenvue brands including Tylenol, Listerine and Neutrogena with Kimberly-Clark's Huggies, Kleenex, Scott and Cottonelle, and will operate through four regional business units under chief executive Mike Hsu. Kimberly-Clark is targeting about USD 2.1bn in annual synergies, including USD 1.9bn of cost savings within three years of closing.

Why this mattersPackaging specifications for Tylenol, Listerine and Neutrogena now sit with a buyer targeting USD 1.9bn of cost savings within three years.

• Deal completed 2 November 2026
• Initial transaction value approximately USD 48.7bn
• Targeted annual synergies of USD 2.1bn, including USD 1.9bn in cost savings within three years of closing
• New group organised into four regional business units under CEO Mike Hsu
• Kenvue brands include Tylenol, Listerine and Neutrogena; Kimberly-Clark brands include Huggies, Kleenex, Scott and Cottonelle
• In July 2026 Kimberly-Clark launched Arbex, a tissue joint venture with Suzano covering 22 mills in 14 countries, retaining a 49% stake

Relevant to you? Yes No